Biodexa Pharmaceuticals Plc

corporate_fare Company Profile

Biodexa Pharmaceuticals Plc

BDRX·NASDAQ·Healthcare·CIK 0001643918

Biodexa Pharmaceuticals PLC is a company that develops drug delivery technologies. The company was originally formed as Midatech Ltd in 2000 in England and Wales. It acquired its core nanoparticle technology and joint ownership of patent rights from Consejo Superior de Investigaciones Cientificas in Madrid, Spain. Midatech Ltd focused on research and development, advancing a gold nanoparticle drug delivery platform to improve medicine delivery for major therapeutic conditions with limited clinical options, specifically targeting certain cancers like liver and brain cancer. To further commercial development, Midatech Pharma PLC was incorporated on September 12, 2014, in England and Wales, serving as the public holding company for Midatech Ltd and Midatech Pharma (Wales) Limited. The company completed its initial public offering of Ordinary Shares in the United Kingdom on December 8, 2014. On December 4, 2015, it acquired DARA Biosciences, Inc., and subsequently listed its Depositary Shares on the NASDAQ Capital Market. On March 24, 2023, shareholders approved a name change to "Biodexa Pharmaceuticals PLC" and the cancellation of Ordinary Shares from trading on AIM, effective April 26, 2023. Midatech Ltd and Midatech Pharma (Wales) Limited were also renamed Biodexa Ltd and Biodexa Pharmaceuticals (Wales) Ltd, respectively. The principal executive and registered offices are in Cardiff, United Kingdom.

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a publicly traded company in the Healthcare sector. Wiseek monitors BDRX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Biodexa Proposes Massive 1:10,000 Ordinary Share Reverse Split, New Deferred Shares, and Highly Dilutive Share Issuance Authority Amidst Going Concern Warning (2026-05-14)
Biodexa Registers Shares for Over 200% Potential Dilution from Warrant Exercises (2026-04-02)
Biodexa Pharmaceuticals Registers Massive Share Resale for Existing Equity Line, Signaling Extreme Dilution (2026-04-02)
Biodexa Secures Syngene Partnership for MTX240 Clinical Trial Manufacturing (2026-04-02)
Biodexa Pharmaceuticals Faces Substantial Doubt on Going Concern Amid Continued Losses and Dilutive Financing Needs (2026-03-27)

Financial Snapshot

Fiscal year ended December 31, 2025

Net Income

-£6.38M GBP

Diluted EPS

-£0.00 GBP

Op. Cash Flow

-£5.59M GBP

Free Cash Flow

-£5.59M GBP

Operating Income

-£8.64M GBP

Cash & Equivalents

£8.53M GBP

Debt / Equity

0.00×

Source: 20-F · filed 2026-03-27 · accession 0001214659-26-003921

Insider Transactions

BDRX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with B →

show_chartPrice Chart

Loading chart...

feed BDRX - Latest Insights

Filing Type

Date Range

BDRX

May 14, 2026, 4:00 PM EDT

Filing Type: 6-K

Importance Score:

Biodexa Proposes Massive 1:10,000 Ordinary Share Reverse Split, New Deferred Shares, and Highly Dilutive Share Issuance Authority Amidst Going Concern Warning

Price at Filing: $3.40

Real-time Price: $3.03

Change: -$0.370 (-11%)

Market Cap: $1.368M

Sentiment: Negative

View Wiseek Article

BDRX

Apr 02, 2026, 4:28 PM EDT

Filing Type: 424B3

Importance Score:

Biodexa Registers Shares for Over 200% Potential Dilution from Warrant Exercises

Price at Filing: $0.8451

Real-time Price: $3.03

Change: +$2.18 (+259%)

Market Cap: $1.368M

Sentiment: Negative

View Wiseek Article

BDRX

Apr 02, 2026, 4:28 PM EDT

Filing Type: 424B3

Importance Score:

Biodexa Pharmaceuticals Registers Massive Share Resale for Existing Equity Line, Signaling Extreme Dilution

Price at Filing: $0.8451

Real-time Price: $3.03

Change: +$2.18 (+259%)

Market Cap: $1.368M

Sentiment: Negative

View Wiseek Article

BDRX

Apr 02, 2026, 8:30 AM EDT

Source: GlobeNewswire

Importance Score:

Biodexa Secures Syngene Partnership for MTX240 Clinical Trial Manufacturing

Price at Filing: $0.6646

Real-time Price: $3.03

Change: +$2.37 (+356%)

Market Cap: $1.368M

Sentiment: Positive

View Wiseek Article

BDRX

Mar 27, 2026, 5:09 PM EDT

Filing Type: 20-F

Importance Score:

Biodexa Pharmaceuticals Faces Substantial Doubt on Going Concern Amid Continued Losses and Dilutive Financing Needs

Price at Filing: $0.672

Real-time Price: $3.03

Change: +$2.36 (+351%)

Market Cap: $1.368M

Sentiment: Negative

View Wiseek Article

BDRX

Mar 27, 2026, 5:02 PM EDT

Source: Dow Jones Newswires

Importance Score:

Biodexa Pharmaceuticals Reports GBP0.01 Loss Per Share for 2025 Operations

Price at Filing: $0.710

Real-time Price: $3.03

Change: +$2.32 (+327%)

Market Cap: $1.368M

Sentiment: Negative

View Wiseek Article

BDRX

Mar 23, 2026, 8:30 AM EDT

Source: GlobeNewswire

Importance Score:

Biodexa Launches Global Early Access Program for eRapa for FAP Patients via Tanner Pharma Partnership

Price at Filing: $0.7298

Real-time Price: $3.03

Change: +$2.30 (+315%)

Market Cap: $1.368M

Sentiment: Positive

View Wiseek Article

BDRX

Mar 18, 2026, 5:11 PM EDT

Filing Type: 6-K

Importance Score:

Biodexa Pharmaceuticals Announces 1-for-5 Reverse ADR Split to Meet Nasdaq Minimum Bid Price

Price at Filing: $0.745201

Real-time Price: $3.03

Change: +$2.28 (+307%)

Market Cap: $1.368M

Sentiment: Negative

View Wiseek Article

BDRX

Feb 04, 2026, 8:49 AM EST

Filing Type: 424B3

Importance Score:

Biodexa Licenses Phase 1 Oncology Asset MTX240 from Otsuka for GIST

Price at Filing: $1.65

Real-time Price: $3.03

Change: +$1.38 (+84%)

Market Cap: $1.368M

Sentiment: Positive

View Wiseek Article

BDRX

Feb 04, 2026, 8:39 AM EST

Filing Type: 6-K

Importance Score:

Biodexa Licenses Phase 1-Ready Molecular Glue for GIST from Otsuka

Price at Filing: $1.82

Real-time Price: $3.03

Change: +$1.21 (+66%)

Market Cap: $1.368M

Sentiment: Positive

View Wiseek Article

BDRX

Jan 06, 2026, 4:07 PM EST

Filing Type: 424B3

Importance Score:

Biodexa Pharmaceuticals Appoints Experienced Group Financial Controller Fiona Sharp as New CFO and Director

Price at Filing: $2.40

Real-time Price: $3.03

Change: +$0.630 (+26%)

Market Cap: $1.368M

Sentiment: Positive

View Wiseek Article

BDRX

Jan 06, 2026, 4:07 PM EST

Filing Type: 424B3

Importance Score:

Biodexa Pharmaceuticals Appoints Fiona Sharp as New CFO and Director

Price at Filing: $2.40

Real-time Price: $3.03

Change: +$0.630 (+26%)

Market Cap: $1.368M

Sentiment: Positive

View Wiseek Article

BDRX

Jan 06, 2026, 4:07 PM EST

Filing Type: 424B3

Importance Score:

Biodexa Pharmaceuticals Appoints Fiona Sharp as Chief Financial Officer and Director

Price at Filing: $2.40

Real-time Price: $3.03

Change: +$0.630 (+26%)

Market Cap: $1.368M

Sentiment: Positive

View Wiseek Article

BDRX

Jan 06, 2026, 4:07 PM EST

Filing Type: 424B3

Importance Score:

Massive Share Resale Prospectus Filed by Biodexa Pharmaceuticals, New CFO Appointed

Price at Filing: $2.40

Real-time Price: $3.03

Change: +$0.630 (+26%)

Market Cap: $1.368M

Sentiment: Negative

View Wiseek Article

BDRX

Jan 05, 2026, 8:30 AM EST

Filing Type: 6-K

Importance Score:

Biodexa Pharmaceuticals Appoints Fiona Sharp as CFO and Board Member

Price at Filing: $2.53

Real-time Price: $3.03

Change: +$0.500 (+20%)

Market Cap: $1.368M

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile